Dr. En Li was appointed General Manager, China Novartis Institutes for Biomedical Research (CNIBR) and Head, NIBR Shanghai in 2007.He joined Novartis as Vice President and Global Head, Models of Disease Center and Epigenetics Program in 2003. Prior to that, he was Associate Professor of Medicine at Harvard Medical School, and a Principal Investigator of the Cardiovascular Research Center and Cancer Center at Massachusetts General Hospital.
En is a scientific leader in the field of Epigenetics. He discovered de novo DNA methyltransferases that establish the DNA methylation patternsof the human genome and made important contributions to the understanding of the functions of DNA methylation in development and diseases. His research interests also include histone modifications, mammalian development, stem cell and tissue regeneration. He has published more than 100 research papers and review articles in major scientific journals. En received his bachelor of science degree in biochemistry from Peking University and a Ph.D. in Biology from Massachusetts Institute of Technology.
美 国马里兰大学植物分子生物学博士。1995-1999年，先后在美国孟山都公司担任博士后研究员和高级研究员，从事基因发现和基因表达工 作。 1999-2002年在美国Core Genomics and Applications Large Scale Biology 公 司担任 研发总监。2002至今，先后担任新加坡基因组研究院资深研究员和副所长。06年获聘新加坡国立大学副教授。阮义军教授主要致力于新的大规模测序 技术的 开发和 应用，先后在包括在《自然》和《细胞》等杂志发表多篇有影响力的论文。曾获颁新加坡国家科学奖。
Prof. Cao was born in Shandong, China and received his medical training at the Medical School, Shandong University in 1983. 1983-1986, he received further basic and clinical training from the Chinese Academy of Medical Sciences and from the Ludwig Institute for Cancer Research, Switzerland. He obtained his Ph.D. degree in 1993 from the Karolinska Institutet, followed by a 3yr postdoctoral training period at the Harvard Medical School, Children’s Hospital (Dr. Judah Folkma´s Laboratory), Boston, Massachusetts, USA. He returned to the Karolinska Institutet in 1996 and became a full professor in 2004.
He received an honorary medical degree (M.D.) from Copenhagen University, Denmark, 2006. He is currently a guest professor at the Linköping University, Sweden. He received the Fernstrom research prize. In 2010, Dr Cao received the distinguished professor award at the Karolinska Institutet. Dr. Cao also received the ERC-advanced research grant award for being the top scientist in Europe. His research interests include molecular mechanisms of pathological angiogenesis that contributes to obesity, metabolic diseases, diabetic complications, cancer, metastasis, and cardiovascular diseases, with emphasis on clinical relevance and translational research. He has published more than 160 research articles, which have been cited more than 11 000 times.